Lyka Labs Balance Sheet Annual

Trade

BSE: 500259 | NSE: LYKALABS | ISIN: INE933A01014 | Sector: Biotechnology & Drugs

147.00 +3.65 (2.55%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Cash Equivalents	5.95	11.71	17.05	7.15
Short Term Investments	3.43	2.56	1.77	0.99
Cashand Short Term Investments	9.38	14.27	18.82	8.14
Accounts Receivable- Trade Net	26.99	20.13	18.45	8.67
Total Receivables Net	27.05	20.21	18.50	8.74
Total Inventory	9.57	6.95	8.20	4.31
Other Current Assets Total	4.65	2.77	6.68	7.94
Total Current Assets	50.65	44.20	52.20	29.12
Property/ Plant/ Equipment Total- Net	68.84	63.67	85.60	83.66
Intangibles Net	11.91	20.65	26.10	40.29
Long Term Investments	16.83	16.34	14.37	13.77
Note Receivable- Long Term	1.03	5.62	6.03	5.41
Other Long Term Assets Total	7.46	1.03	1.32	17.76
Total Assets	156.72	151.52	185.61	190.01
Accounts Payable	12.10	9.41	12.00	14.72
Notes Payable/ Short Term Debt	13.66	7.92	67.12	10.37
Current Portof LT Debt/ Capital Leases	0.82	1.32	0.83	0.58
Other Currentliabilities Total	11.05	13.96	19.41	23.57
Total Current Liabilities	37.64	32.60	99.35	49.24
Long Term Debt	42.91	63.40	61.63	151.06
Capital Lease Obligations	1.26	2.47	0.86	0.31
Total Long Term Debt	44.17	65.87	62.49	151.36
Total Debt	58.65	75.10	130.44	162.31
Deferred Income Tax	3.83	4.01	4.23	-
Minority Interest	0.11	0.23	0.15	0.70
Other Liabilities Total	2.83	3.37	6.05	14.51
Total Liabilities	88.57	106.08	172.28	215.81
Common Stock Total	33.09	30.69	28.69	28.69
Retained Earnings( Accumulated Deficit)	35.06	14.75	-15.35	-54.49
Total Equity	68.15	45.44	13.34	-25.80
Total Liabilities Shareholders' Equity	156.72	151.52	185.61	190.01
Total Common Shares Outstanding	3.57	3.07	2.87	2.87
Tangible Book Valueper Share Common Eq	15.76	8.08	-4.45	-23.03